{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:50:09Z","timestamp":1792000209637,"version":"4.4.0"},"reference-count":15,"publisher":"Scientific Scholar","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Nephrol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijn.ijn_2_18","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T07:30:04Z","timestamp":1552548604000},"page":"278","source":"Crossref","is-referenced-by-count":67,"title":["Efficacy and safety of canagliflozin in kidney transplant patients"],"prefix":"10.25259","volume":"29","author":[{"given":"Bharat","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaheer","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0971-4065.254177-1","first-page":"32","volume-title":"Active sugar transport in health and disease","author":"Wright","year":"2007","journal-title":"J Intern Med"},{"key":"key-10.4103\/0971-4065.254177-2","first-page":"5","volume-title":"The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia","author":"DeFronzo","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/0971-4065.254177-3","first-page":"101","volume-title":"Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects","author":"Mogensen","year":"1971","journal-title":"Scand J Clin Lab Invest"},{"key":"key-10.4103\/0971-4065.254177-4","first-page":"1272","volume-title":"Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications","author":"Bakris","year":"2009","journal-title":"Kidney Int"},{"key":"key-10.4103\/0971-4065.254177-5","first-page":"520","volume-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/0971-4065.254177-6","first-page":"669","volume-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","author":"Sha","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/0971-4065.254177-7","first-page":"6355","volume-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus","author":"Nomura","year":"2010","journal-title":"J Med Chem"},{"key":"key-10.4103\/0971-4065.254177-8","first-page":"1232","volume-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"key-10.4103\/0971-4065.254177-9","first-page":"463","volume-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/0971-4065.254177-10","first-page":"e75","volume-title":"Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: A case series","author":"Rajasekeran","year":"2017","journal-title":"Diabetes Care"},{"key":"key-10.4103\/0971-4065.254177-11","first-page":"S20","volume-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","author":"List","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"key-10.4103\/0971-4065.254177-12","first-page":"601","volume-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","author":"Devineni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/0971-4065.254177-13","unstructured":"Shawaqfeh MS, Bhinder MT, Halum AS, Harrington C, Muflih S, Do T. Adverse drug events related to canagliflozin: A meta-analysis of randomized, placebo-controlled trials. Adv Pharmacoepidemiol Drug Saf 2015;4:196-202."},{"key":"key-10.4103\/0971-4065.254177-14","first-page":"438","volume-title":"Efficacy and safety of canagliflozin by baseline HbA 1c and known duration of type 2 diabetes mellitus","author":"Wilding","year":"2015","journal-title":"J Diabetes Complications"},{"key":"key-10.4103\/0971-4065.254177-15","doi-asserted-by":"crossref","unstructured":"Kaushal S, Singh H, Thangaraju P, Singh J. Canagliflozin: A novel SGLT2 inhibitor for type 2 diabetes mellitus. N Am J Med Sci 2014;6:107-13.","DOI":"10.4103\/1947-2714.128471"}],"container-title":["Indian Journal of Nephrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T19:44:58Z","timestamp":1712173498000},"score":1,"resource":{"primary":{"URL":"https:\/\/indianjnephrol.org\/efficacy-and-safety-of-canagliflozin-in-kidney-transplant-patients\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"alternative-id":["254177"],"URL":"https:\/\/doi.org\/10.4103\/ijn.ijn_2_18","relation":{},"ISSN":["0971-4065"],"issn-type":[{"value":"0971-4065","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}